Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.
Clin Cancer Res. 2023 Nov 1;29(21):4326-4330. doi: 10.1158/1078-0432.CCR-23-1041.
Clin Cancer Res. 2023.
PMID: 37318379
Free PMC article.
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease.
Horiba MN, Casak SJ, Mishra-Kalyani PS, Roy P, Beaver JA, Pazdur R, Kluetz PG, Lemery SJ, Fashoyin-Aje LA.
Horiba MN, et al.
Clin Cancer Res. 2022 Dec 15;28(24):5244-5248. doi: 10.1158/1078-0432.CCR-22-0617.
Clin Cancer Res. 2022.
PMID: 35960160
Free PMC article.
Item in Clipboard
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
Patel TH, Marcus L, Horiba MN, Donoghue M, Chatterjee S, Mishra-Kalyani PS, Schuck RN, Li Y, Zhang X, Fourie Zirkelbach J, Charlab R, Liu J, Yang Y, Lemery SJ, Pazdur R, Theoret MR, Fashoyin-Aje LA.
Patel TH, et al. Among authors: horiba mn.
Clin Cancer Res. 2023 Mar 1;29(5):838-842. doi: 10.1158/1078-0432.CCR-22-2036.
Clin Cancer Res. 2023.
PMID: 36206041
Free PMC article.
Item in Clipboard
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Kim GJ, Koshy M, Hanlon AL, Horiba MN, Edelman MJ, Burrows WM, Battafarano RJ, Suntharalingam M.
Kim GJ, et al. Among authors: horiba mn.
Am J Clin Oncol. 2016 Apr;39(2):136-41. doi: 10.1097/COC.0000000000000036.
Am J Clin Oncol. 2016.
PMID: 24487417
Free PMC article.
Item in Clipboard
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL.
Catenacci DV, et al. Among authors: horiba mn.
J Clin Oncol. 2015 Dec 20;33(36):4284-92. doi: 10.1200/JCO.2015.62.8719. Epub 2015 Nov 2.
J Clin Oncol. 2015.
PMID: 26527777
Free PMC article.
Clinical Trial.
Item in Clipboard
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, Horiba MN, Egorin MJ, Ivy P, Pacey S, Lorusso PM.
Vaishampayan UN, et al. Among authors: horiba mn.
Clin Cancer Res. 2010 Jul 15;16(14):3795-804. doi: 10.1158/1078-0432.CCR-10-0503. Epub 2010 Jun 4.
Clin Cancer Res. 2010.
PMID: 20525756
Free PMC article.
Clinical Trial.
Item in Clipboard
Glu-857 moderates K+-dependent stimulation and SCH 28080-dependent inhibition of the gastric H,K-ATPase.
Rulli SJ, Horiba MN, Skripnikova E, Rabon EC.
Rulli SJ, et al. Among authors: horiba mn.
J Biol Chem. 1999 May 21;274(21):15245-50. doi: 10.1074/jbc.274.21.15245.
J Biol Chem. 1999.
PMID: 10329734
Free article.
Item in Clipboard
Cite
Cite